Daiken Biomedical Co

Daiken Biomedical Co Current Ratio

The Current Ratio of Daiken Biomedical Co (7780.TWO) as of Nov 22, 2026 is 6.56. In the previous year, Current Ratio was 1.63 — a change of 301.41% (higher).

Current Ratio

6.56

YoY

301.41%

Last updated:

Current Ratio of Daiken Biomedical Co is 2024 6.56 . Current Ratio of Daiken Biomedical Co was 2023 1.63 . It decreases by 301.41% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Daiken Biomedical Co Stock analysis

What does Daiken Biomedical Co do? Daiken Biomedical Co Ltd generates revenue through the research, development, and sales of health food products. Its main offerings include fish oil, lutein, maca, bitter melon peptide cinnamon capsules, women's probiotics, good sleep sesamin, and high dietary fiber powder packets. The company sells these products via its official website, online platforms like momo, Shopee, and PChome, as well as physical stores such as Watsons, FamilyMart, and Cosmetics. The primary market for these products is Taiwan, where the firm focuses its sales efforts. The company's product portfolio targets health-conscious consumers seeking dietary supplements and wellness solutions. Sales channels combine digital and physical retail, leveraging online marketplaces and convenience stores to reach a broad customer base. Taiwan remains the core market, with no mention of international expansion in the provided business description. Daiken Biomedical's revenue streams are derived from direct sales of its health food products through both online and offline retail channels. The firm emphasizes its presence in Taiwan's domestic market, utilizing established platforms like Watsons and FamilyMart to distribute its branded health supplements. The company's focus on specific health categories like women's wellness and sleep support aligns with consumer demand in the region. Daiken Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Daiken Biomedical Co stock

Current Ratio of Daiken Biomedical Co is 6.56 in 2024.

Current Ratio of Daiken Biomedical Co changed from 1.63 to 6.56, representing a 301.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Ratio Daiken Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's Daiken Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Daiken Biomedical Co

All Key Metrics — Daiken Biomedical Co